No clear evidence that most new cancer drugs enhance life
Most cancer drugs approved in Europe between 2009 and 2013 entered the market without clear evidence they improved survival or quality of life. Even where drugs did show patient survival gains over existing treatments, these were often marginal, a study found.
Nursing Standard.
32, 9, 16-16.
doi: 10.7748/ns.32.9.16.s18
Want to read more?
Already have access? Log in
or
3-month trial offer for £5.25/month
Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
- Unlimited access to all 10 RCNi Journals
- RCNi Learning featuring over 175 modules to easily earn CPD time
- NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
- Personalised newsletters tailored to your interests
- A customisable dashboard with over 200 topics
Subscribe
Alternatively, you can purchase access to this article for the next seven days.
Buy now
Are you a student? Our student subscription has content especially for you.
Find out more
